Zevra Therapeutics (ZVRA) Short term Debt (2014 - 2023)
Zevra Therapeutics (ZVRA) posted Short term Debt of $37.7 million for Q4 2023, up 5419.77% on a QoQ basis from $683000.0 in Q1 2021.
Zevra Therapeutics (ZVRA) Short term Debt (2014 - 2023) Analysis & Trends
Zevra Therapeutics' Short term Debt history runs 5 years deep, the most recent figure standing at $37.7 million for Q4 2023.
- Quarterly Short term Debt changed N/A year-over-year to $37.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $37.7 million (changed N/A YoY) and the FY2023 annual result came in at $37.7 million, changed N/A from the prior year.
- Short term Debt was $37.7 million for Q4 2023 at Zevra Therapeutics, up from $683000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $37.7 million in Q4 2023 and bottomed at $390000.0 in Q4 2020.
- A 3-year average of $12.9 million and a median of $683000.0 in 2021 frame the typical range for Short term Debt.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 37.70 Mn |
| Mar 31, 2021 | 683,000.00 |
| Dec 31, 2020 | 390,000.00 |
| Dec 31, 2015 | 2.04 Mn |
| Sep 30, 2015 | 1.63 Mn |
| Dec 31, 2014 | 482,000.00 |